A detailed history of China Universal Asset Management Co., Ltd. transactions in Spring Works Therapeutics, Inc. stock. As of the latest transaction made, China Universal Asset Management Co., Ltd. holds 14,194 shares of SWTX stock, worth $529,152. This represents 0.09% of its overall portfolio holdings.

Number of Shares
14,194
Previous 14,194 -0.0%
Holding current value
$529,152
Previous $699,000 0.14%
% of portfolio
0.09%
Previous 0.09%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

Apr 29, 2024

BUY
$36.5 - $52.5 $253,930 - $365,242
6,957 Added 96.13%
14,194 $699,000
Q4 2023

May 21, 2024

SELL
$18.94 - $37.24 $131,765 - $259,078
-6,957 Reduced 49.01%
7,237 $264,000
Q4 2023

Jan 23, 2024

BUY
$18.94 - $37.24 $106,537 - $209,475
5,625 Added 348.95%
7,237 $264,000
Q3 2023

May 21, 2024

BUY
$23.12 - $31.38 $18,311 - $24,852
792 Added 96.59%
1,612 $37,000
Q3 2023

Oct 30, 2023

BUY
$23.12 - $31.38 $18,311 - $24,852
792 Added 96.59%
1,612 $37,000
Q2 2023

May 21, 2024

SELL
$23.15 - $32.71 $625 - $883
-27 Reduced 3.19%
820 $21,000
Q2 2023

Jul 27, 2023

SELL
$23.15 - $32.71 $625 - $883
-27 Reduced 3.19%
820 $22,000
Q1 2023

May 21, 2024

BUY
$24.97 - $34.05 $5,318 - $7,252
213 Added 33.6%
847 $21,000
Q1 2023

Apr 27, 2023

BUY
$24.97 - $34.05 $5,318 - $7,252
213 Added 33.6%
847 $22,000
Q4 2022

May 21, 2024

SELL
$21.73 - $28.72 $294,658 - $389,443
-13,560 Reduced 95.53%
634 $16,000
Q4 2022

Jan 31, 2023

BUY
$21.73 - $28.72 $3,715 - $4,911
171 Added 36.93%
634 $16,000
Q3 2022

Oct 21, 2022

BUY
$24.1 - $39.66 $11,158 - $18,362
463 New
463 $13,000

Others Institutions Holding SWTX

About SpringWorks Therapeutics, Inc.


  • Ticker SWTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 62,401,100
  • Market Cap $2.33B
  • Description
  • SpringWorks Therapeutics, Inc. acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that is in Phase III clinical trial for the treatment of desmoid tumors. The company is also deve...
More about SWTX
Track This Portfolio

Track China Universal Asset Management Co., Ltd. Portfolio

Follow China Universal Asset Management Co., Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of China Universal Asset Management Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on China Universal Asset Management Co., Ltd. with notifications on news.